Pathophysiology of preeclampsia: An angiogenic imbalance and long-lasting systemic vascular dysfunction

Hypertension Research

Volumn 40, Issue 4, 2017, Pages 305-310

  Tomimatsu, Takuji ^a   Mimura, Kazuya ^a   Endo, Masayuki ^a   Kumasawa, Keiichi ^a   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenic imbalance; preeclampsia; soluble fms like tyrosine kinase 1; systemic vascular dysfunction

Indexed keywords

VASCULOTROPIN;

CARDIOVASCULAR RISK; CYTOTROPHOBLAST; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HUMAN; MORBIDITY; MORTALITY; PREECLAMPSIA; PREGNANCY; PROTEINURIA; RENOVASCULAR DISEASE; REVIEW; RISK FACTOR; FEMALE; KIDNEY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PRE-ECLAMPSIA; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 85017121022     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2016.152     Document Type: Review

References (122)

1. Cunningham FD. Hypertensive Disorders, Williams Obstetrics 24th edn. McGraw-Hill Education, 2014, pp 728-779.
2. Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005; 365: 785-799.
3. Wenger NK. Recognizing pregnancy-associated cardiovascular risk factors. Am J Cardiol 2014; 113: 406-409.
4. Veerbeek JH, Hermes W, Breimer AY, van Rijn BB, Koenen SV, Mol BW, Franx A, de Groot CJ, Koster MP. Cardiovascular disease risk factors after early-onset preeclampsia, late-onset preeclampsia, and pregnancy-induced hypertension. Hypertension 2015; 65: 600-606.
5. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014; 63: 1815-1822.
6. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989; 161: 1200-1204.
7. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 2015; 24: 131-138.
8. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 2014; 10: 466-480.
9. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594.
10. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
11. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl JMed 2004; 350: 672-683.
12. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
13. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SACPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
14. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200: 481.e1-7.
15. Stella CL, Malik KM, Sibai BM. HELLP syndrome: an atypical presentation. Am J Obstet Gynecol 2008; 198: e6-e8.
16. Ohno Y, Terauchi M, Tamakoshi K, Shiozaki A, Saito S. The risk factors for labor onset hypertension. Hypertens Res 2016; 39: 260-265.
17. Puttapitakpong P, Phupong V. Combination of serum angiopoietin-2 and uterine artery Doppler for prediction of preeclampsia. Hypertens Res 2016; 39: 95-99.
18. Taebi M, Sadat Z, Saberi F, Kalahroudi MA. Early pregnancy waist-to-hip ratio and risk of preeclampsia: a prospective cohort study. Hypertens Res 2015; 38: 80-83.
19. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009; 30(Suppl A): S32-S37.
20. De Wolf F, De Wolf-Peeters C, Brosens I, Robertson WB. The human placental bed: electron microscopic study of trophoblastic invasion of spiral arteries. Am J Obstet Gynecol 1980; 137: 58-70.
21. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139-2151.
22. Brosens IA, Robertson WB, Dixon HG. The role of the spiral arteries in the pathogenesis of preeclampsia. Obstet Gynecol Annu 1972; 1: 177-191.
23. Robertson WB, Brosens I, Dixon HG. The pathological response of the vessels of the placental bed to hypertensive pregnancy. J Pathol Bacteriol 1967; 93: 581-592.
24. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648-655.
25. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993; 91: 950-960.
26. Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010; 63: 601-610.
27. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, Takeda S, Yano T, Tsutsumi O, Taketani Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003; 88: 2348-2351.
28. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563.
29. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709.
30. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995; 129: 895-898.
31. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-1548.
32. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989; 84: 1470-1478.
33. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
34. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-1309.
35. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
36. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108: 1451-1455.
37. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
38. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127-3139.
39. Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y, Momoeda M, Kozuma S, Taketani Y. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004; 145: 4838-4845.
40. Fan X, Rai A, Kambham N, Sung JF, Singh N, Petitt M, Dhal S, Agrawal R, Sutton RE, Druzin ML, Gambhir SS, Ambati BK, Cross JC, Nayak NR. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest 2014; 124: 4941-4952.
41. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108: 1063-1070.
42. Miyake T, Kumasawa K, Sato N, Takiuchi T, Nakamura H, Kimura T. Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells. Sci Rep 2016; 6: 24853.
43. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008; 21: 9-23.
44. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
45. Mashini IS, Albazzaz SJ, Fadel HE, Abdulla AM, Hadi HA, Harp R, Devoe LD. Serial noninvasive evaluation of cardiovascular hemodynamics during pregnancy. Am J Obstet Gynecol 1987; 156: 1208-1213.
46. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol 1989; 256: H1060-H1065.
47. Duvekot JJ, Cheriex EC, Pieters FA, Menheere PP, Peeters LH. Early pregnancy changes in hemodynamics and volume homeostasis are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol 1993; 169: 1382-1392.
48. Mabie WC, DiSessa TG, Crocker LG, Sibai BM, Arheart KL. A longitudinal study of cardiac output in normal human pregnancy. Am J Obstet Gynecol 1994; 170: 849-856.
49. Christianson RE. Studies on blood pressure during pregnancy. I. Influence of parity and age. Am J Obstet Gynecol 1976; 125: 509-513.
50. Moutquin JM, Rainville C, Giroux L, Raynauld P, Amyot G, Bilodeau R, Pelland N. A prospective study of blood pressure in pregnancy: prediction of preeclampsia. Am J Obstet Gynecol 1985; 151: 191-196.
51. Cornelis T, Odutayo A, Keunen J, Hladunewich M. The kidney in normal pregnancy and preeclampsia. Semin Nephrol 2011; 31: 4-14.
52. Mattot V, Moons L, Lupu F, Chernavvsky D, Gómez RA, Collen D, Carmeliet P. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J Am Soc Nephrol 2002; 13: 1548-1560.
53. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15.
54. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
55. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
56. Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010; 74: 24-33.
57. McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006; 48: 602-608.
58. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 2011; 57: 363-369.
59. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 2013; 168: 344-351.
60. Dørup I, Skajaa K, Sørensen KE. Normal pregnancy is associated with enhanced endothelium-dependent flow-mediated vasodilation. Am J Physiol 1999; 276(3 Pt 2): H821-H825.
61. Weissgerber TL, Milic NM, Milin-Lazovic JS, Garovic VD. Impaired flow-mediated dilation before, during, and after preeclampsia: a systematic review and meta-analysis. Hypertension 2016; 67: 415-423.
62. Kelly R, Hayward CS, Avolio A, O'Rourke MF. Non-invasive registration of the arterial pressure pulse waveform using high-fidelity applanation tonometry. J Vasc Med Biol 1989; 1: 142-149.
63. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005; 18: 3S-10S.
64. Nichols WW, Singh BM. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol 2002; 17: 543-551.
65. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JRACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005; 46: 1753-1760.
66. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
67. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197-203.
68. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Willens HJ, Perez G, Mendez AJ. Aortic pressure augmentation predicts adverse cardiovascular events in patients with established coronary artery disease. Hypertension 2005; 45: 980-985.
69. London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434-438.
70. Fujime M, Tomimatsu T, Okaue Y, Koyama S, Kanagawa T, Taniguchi T, Kimura T. Central aortic blood pressure and Augmentation index during normal pregnancy. Hypertens Res 2012; 35: 633-638.
71. Macedo ML, Luminoso D, Savvidou MD, McEniery CM, Nicolaides KH. Maternal wave reflections and arterial stiffness in normal pregnancy as assessed by applanation tonometry. Hypertension 2008; 51: 1047-1051.
72. Khalil A, Jauniaux E, Cooper D, Harrington K. Pulse wave analysis in normal pregnancy: a prospective longitudinal study. PLoS ONE 2009; 4: e6134.
73. Spasojevic M, Smith SA, Morris JM, Gallery ED. Peripheral arterial pulse wave analysis in women with pre-eclampsia and gestational hypertension. BJOG 2005; 112: 1475-1478.
74. Khalil A, Jauniaux E, Harrington K. Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. Obstet Gynecol 2009; 113: 646-654.
75. Khalil AA, Cooper DJ, Harrington KF. Pulse wave analysis: a preliminary study of a novel technique for the prediction of pre-eclampsia. BJOG 2009; 116: 268-276.
76. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11-13 weeks' gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012; 40: 28-34.
77. Tomimatsu T, Fujime M, Kanayama T, Mimura K, Koyama S, Kanagawa T, Kimura T. Maternal arterial stiffness in normotensive pregnant women who subsequently deliver babies that are small for gestational age. Eur J Obstet Gynecol Reprod Biol 2013; 169: 24-27.
78. Tomimatsu T, Fujime M, Kanayama T, Mimura K, Koyama S, Kanagawa T, Endo M, Shimoya K, Kimura T. Abnormal pressure-wave reflection in pregnant women with chronic hypertension: association with maternal and fetal outcomes. Hypertens Res 2014; 37: 989-992.
79. Rogers DT, Colon M, Gambala C, Wilkins I, Hibbard JU. Effects of magnesium on central arterial compliance in preeclampsia. Am J Obstet Gynecol 2010; 202: 448.e1-8.
80. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, Cherney DZ, Hladunewich MA. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122: 1846-1853.
81. Asmar R. Pulse wave velocity: principle and measurement. In Asmar R (ed.). Arterial Stiffness and Pulse Wave Velocity. Amsterdam: Elsevier, 1999, pp 25-56.
82. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-670.
83. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10-15.
84. Oyama-Kato M, Ohmichi M, Takahashi K, Suzuki S, Henmi N, Yokoyama Y, Kurachi H. Change in pulse wave velocity throughout normal pregnancy and its value in predicting pregnancy-induced hypertension: a longitudinal study. Am J Obstet Gynecol 2006; 195: 464-469.
85. Kaihura C, Savvidou MD, Anderson JM, McEniery CM, Nicolaides KH. Maternal arterial stiffness in pregnancies affected by preeclampsia. Am J Physiol Heart Circ Physiol 2009; 297: H759-H764.
86. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856-2869.
87. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17: 3-18.
88. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919.
89. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009; 22: 1021-1038.
90. Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE 2010; 5: e13263.
91. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 2012; 207: 407.e1-7.
92. Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, Mol BW, Pajkrt EEBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119: 778-787.
93. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016; 374: 13-22.
94. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS. Maternal plasma concentrations of angiogenic/antiangiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-1207.
95. Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, Cerdeira AS, Verlohren S, Perschel FH, Arany Z, Lim KH, Thadhani R, Karumanchi SA. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy 2013; 32: 189-201.
96. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202: 161.e1-161.e11.
97. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202: 40.e1-7.
98. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012; 59: 740-746.
99. Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, Ferraresi M, Todros T, Piccoli GB. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 2013; 83: 177-181.
100. Leaños-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, Molina-Pérez CJ, García-Paleta Y, Isordia-Salas I, Ramírez-Valenzuela KL. Circulating angiogenic factors and the risk of preeclampsia in systemic lupus erythematosus pregnancies. J Rheumatol 2015; 42: 1141-1149.
101. Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008; 35: 631-634.
102. Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010; 23: 366-370.
103. Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, Suzuki M, Sato Y. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension 2009; 54: 1129-1135.
104. Gilbert JS, Verzwyvelt J, Colson D, Arany M, Karumanchi SA, Granger JP. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010; 55: 380-385.
105. Mimura K, Tomimatsu T, Sharentuya N, Tskitishvili E, Kinugasa-Taniguchi Y, Kanagawa T, Kimura T. Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia. Am J Obstet Gynecol 2010; 202(464): e1-e6.
106. Kakigano A, Tomimatsu T, Mimura K, Kanayama T, Fujita S, Minato K, Kumasawa K, Taniguchi Y, Kanagawa T, Endo M, Ishihara T, Namba T, Mizushima T, Kimura T. Drug repositioning for preeclampsia therapeutics by in vitro screening: phosphodiesterase-5 inhibitor vardenafil restores endothelial dysfunction via induction of placental growth factor. Reprod Sci 2015; 22: 1272-1280.
107. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950.
108. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, Easterling TR, Haas DM, Haneline LS, Caritis SN, Venkataramanan R, West H, D'Alton M, Hankins G, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214: 720.e1-720.e17.
109. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129290 births. Lancet 2001; 357: 2002-2006.
110. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974.
111. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y. Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 2009; 104: 1478-1483.
112. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485: 333-338.
113. Kvehaugen AS, Dechend R, Ramstad HB, Troisi R, Fugelseth D, Staff AC. Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension 2011; 58: 63-69.
114. Akhter T, Wikström AK, Larsson M, Larsson A, Wikström G, Naessen T. Association between angiogenic factors and signs of arterial aging in women with pre-eclampsia. Ultrasound Obstet Gynecol (e-pub ahead of print 3 June 2016; doi:10.1002/uog.15981).
115. Kurabayashi T, Mizunuma H, Kubota T, Kiyohara Y, Nagai K, Hayashi K. Pregnancy-induced hypertension is associated with maternal history and a risk of cardiovascular disease in later life: Japanese cross-sectional study. Maturitas 2013; 75: 227-231.
116. Nohira T. Hypertension and metabolic abnormalities later in life after preeclampsia. Hypertens Res Pregnancy 2013; 1: 52-56.
117. Hosaka M, Asayama K, Staessen JA, Tatsuta N, Satoh M, Kikuya M, Ohkubo T, Satoh H, Imai Y, Nakai K. Relationship between maternal gestational hypertension and home blood pressure in 7-year-old children and their mothers: Tohoku Study of Child Development. Hypertens Res 2015; 38: 776-782.
118. Watanabe K, Kimura C, Iwasaki A, Mori T, Matsushita H, Shinohara K, Wakatsuki A, Gosho M, Miyano I. Pregnancy-induced hypertension is associated with an increase in the prevalence of cardiovascular disease risk factors in Japanese women. Menopause 2015; 22: 656-659.
119. Berks D, Hoedjes M, Raat H, Duvekot JJ, Steegers EA, Habbema JD. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study. BJOG 2013; 120: 924-931.
120. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Piña IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011; 123: 1243-1262.
121. Takagi K, Yamasaki M, Nakamoto O, Saito S, Suzuki H, Seki H, Takeda S, Ohno Y, Sugimura M, Suzuki Y, Watanabe K, Matsubara K, Makino S, Metoki H, Yamamoto T. A review of Best Practice Guide 2015 for care and treatment of hypertension in pregnancy. Hypertens Res Pregnancy 2015; 3: 65-103.
122. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura SJapanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253-390.